Accuray Incorp Stock Price, News & Analysis

Accuray (NASDAQ: ARAY) announced the first patient treatments with the CyberKnife® System in Austria at the CyberKnife® Center Salzburg. The center utilized Accuray's CyberComm™ technology to commission their latest-generation CyberKnife S7™ System, reducing commissioning time by approximately 50%. The system delivers ultra-hypofractionated radiation therapy in just 1-5 outpatient sessions, compared to conventional 30-40 sessions, with sub-millimeter accuracy.

This installation is particularly significant as Austria's radiotherapy equipment supply is 27% lower than the EU average and 34% lower than economic peers, while cancer cases are projected to increase by 25% between 2022 and 2040. The CyberKnife System's introduction aims to address this healthcare gap and provide more efficient cancer treatment options for Austrian patients.

Accuray reported its fiscal 2025 third quarter results, showing notable improvements in financial performance. The company achieved total net revenue of $113.2 million, marking a 12% increase year-over-year. The quarter saw reduced losses, with net loss decreasing to $1.3 million compared to $6.3 million in the prior year.

Key financial highlights include:

• Product revenue increased 16% to $57.3 million
• Service revenue grew 9% to $55.9 million
• Adjusted EBITDA improved to $6.0 million from $1.1 million
• Cash position strengthened to $78.8 million

Despite facing tariff challenges, the company maintained resilient performance. However, order backlog decreased 10% to $452.4 million. For fiscal year 2025, Accuray reaffirmed its adjusted EBITDA guidance of $28.5-31.0 million but adjusted revenue guidance to $452-460 million due to tariff impacts on product volume.

Accuray (NASDAQ: ARAY) has announced it will release its third quarter fiscal 2025 financial results on April 30, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results for the quarter ended March 31, 2025.

Investors can access the conference call via USA dial-in (1-833-316-0563) or international dial-in (1-412-317-5747). A replay will be available for one week through 1-877-344-7529 (USA) or 1-412-317-0088 (international) using conference ID 8141169. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q4 FY2025 results announcement.

Accuray (NASDAQ: ARAY) presented new clinical data for its CyberKnife® System at the 2025 Radiosurgery Society Scientific Meeting, demonstrating its effectiveness in treating central nervous system tumors. Key findings include:

- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments

- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases

- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination

- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief

The CyberKnife System utilizes image guidance during treatment, leveraging up to 1,000 different beam angles and Synchrony® adaptive delivery technology to adjust for tumor or patient motion in real-time.

Accuray (NASDAQ: ARAY) has announced its participation in the 37th Annual Roth Conference scheduled for March 16-18, 2025, in Dana Point, California. The company's management will engage in a fireside chat on March 18, 2025, at 9:30am PT / 12:30pm ET, and will be available for one-on-one investor meetings.

A live webcast of the fireside chat will be accessible through their website at investors.accuray.com, with replay available for 90 days after the presentation. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for oncology and neuro-radiosurgery, focusing on developing innovative treatments for complex cases while simplifying common procedures.

Accuray (NASDAQ: ARAY) reported strong fiscal Q2 2025 results with total net revenue of $116.2 million, an 8% year-over-year increase. The company achieved a net income of $2.5 million compared to a $9.6 million loss in the prior year period. Product revenue increased 19% to $61.2 million, while service revenue slightly decreased by 1% to $55.0 million.

Gross profit improved to $41.9 million (36.1% of revenue) from $35.9 million (33.5%) year-over-year. Operating expenses decreased 7% to $37.2 million. The company's adjusted EBITDA reached $9.6 million, up from $2.0 million in the prior year. Based on strong performance, Accuray raised its fiscal year 2025 guidance, projecting revenue between $463-475 million and adjusted EBITDA of $28.5-31.0 million.

Accuray (NASDAQ: ARAY) announced a significant milestone as Shandong Cancer Hospital and Institute completed treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. The hospital, which was the first in China to receive the system, can now treat an average of 95 patient treatment fractions daily.

This achievement is particularly significant given China's projected increase in cancer cases, with expectations of 7.1 million diagnoses by 2045, up from 4.8 million in 2022 - a 47% increase. The Tomo C System, based on the helical TomoTherapy® platform, is designed to provide ultra-precise treatments while enabling higher patient throughput, addressing the growing needs of China's underserved radiation therapy market.